Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3–4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study

Apr 30, 2024Advances in therapy

Return of High Blood Potassium After Diet Treatment in Patients with Moderate to Severe Chronic Kidney Disease

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

In a cohort of 2048 patients with stage 3-4 chronic kidney disease, 56.0% experienced at least one recurrence of during a 6-month follow-up.

Patients with hyperkalemia had a mean of 2.6 recurrences during the follow-up period.
37.4% of patients had at least one recurrence within the first month after .
The mean time to the first hyperkalemia recurrence was 45 days, with shorter intervals between subsequent episodes.
Hyperkalemia-related hospitalizations occurred in 13.7% of patients, while 1.5% had emergency department visits.
Results were consistent across subgroups, including those with heart failure and those on specific hypertension medications.

AI simplified

INTRODUCTION: The REVOLUTIONIZE I study aimed to characterize the relationships between (MNT) and recurrence in patients with stage 3-4 chronic kidney disease (CKD) and hyperkalemia who received MNT in real-world clinical practice.

METHODS: This observational cohort study used de-identified electronic health record data from patients aged ≥ 18 years with stage 3-4 CKD who received MNT between January 2019 and October 2022 and had hyperkalemia (serum potassium > 5.0 mmol/L) within 30 days before MNT. Patients were followed for 6 months or until the first censoring event (death, prescription of outpatient potassium binder, or study end). The primary outcome was the percentage of patients with ≥ 1 hyperkalemia recurrence during follow-up. Secondary outcomes included the number of hyperkalemia recurrences per patient, time to each recurrence, and hyperkalemia-related healthcare resource utilization. Exploratory outcomes included all-cause healthcare resource utilization and mortality.

RESULTS: The final cohort comprised 2048 patients; 1503 (73.4%) patients remained uncensored after 6 months. During the 6-month follow-up period, 56.0% of patients had ≥ 1 hyperkalemia recurrence and 37.4% had ≥ 1 recurrence within the first month. Patients with ≥ 1 hyperkalemia recurrence during follow-up had a mean ± standard deviation (SD) of 2.6 ± 2.2 recurrences. The mean ± SD time to first hyperkalemia recurrence was 45 ± 46 days; the time between recurrences decreased with subsequent episodes. Hyperkalemia-related hospitalizations and emergency department visits were recorded for 13.7% and 1.5% of patients, respectively. Sensitivity analyses showed that results were consistent across patient subgroups, including those with comorbid heart failure and patients receiving renin-angiotensin-aldosterone system inhibitor therapy at baseline.

CONCLUSION: Most patients with stage 3-4 CKD had hyperkalemia recurrence, and MNT alone was inadequate to prevent recurrence. These patients may require additional long-term treatment, such as novel potassium binders, to maintain normokalemia and prevent hyperkalemia recurrence following MNT. Infographic available for this article. INFOGRAPHIC.

Key numbers

56.0%

Recurrence Rate

Percentage of patients with at least one recurrence during follow-up.

2.6

Mean Recurrences

Average number of recurrences per patient during the follow-up.

13.7%

Hospitalization Rate

Percentage of patients requiring -related hospitalizations.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text (HTML) ↗

Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3–4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief

Abstract

Key numbers

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief